Engineered immune cells take on Hard-to-Treat lymphoma
NCT ID NCT03434769
First seen Mar 02, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This early-phase study tests whether a patient's own immune cells, modified in a lab to recognize and attack lymphoma cells, can shrink tumors or stop the cancer from growing. The treatment is for people with non-Hodgkin lymphoma that has not responded to or has returned after at least two prior therapies. The main goals are to see if the cancer responds and to understand the side effects of this approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.